The Prescription Without a Foundation

What the GLP-1 literature is telling us — and what current prescribing practice is leaving out.

The emergence of GLP-1 receptor agonists as a treatment for obesity and metabolic dysfunction represents one of the most significant pharmacological developments in recent medical history. The clinical outcomes in landmark trials have been compelling. In the STEP 1 trial, semaglutide produced mean body weight reductions of approximately 14.9% over 68 weeks in adults with obesity — a result that significantly outperformed prior pharmacological interventions.

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002. DOI: 10.1056/NEJMoa2032183

The SURMOUNT-1 trial demonstrated even more substantial outcomes with tirzepatide, showing weight reductions of up to 20.9% in the highest dose group over 72 weeks.

Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216. DOI: 10.1056/NEJMoa2206038

These are not trivial findings. For patients who have struggled with metabolic dysfunction, insulin resistance, and weight management for years — sometimes decades — these medications have produced outcomes that diet and lifestyle intervention alone rarely achieved in a clinical setting constrained by time, resources, and the complexity of human behavior.

And yet the literature, examined carefully and in full, tells a more complicated story. One that current prescribing practice has been slow to integrate — and that patients navigating these medications largely without nutritional guidance deserve to understand.

What the trials actually measured — and what they did not.

The primary endpoints of the major GLP-1 trials were percentage of total body weight lost and improvements in cardiometabolic markers — HbA1c, fasting glucose, blood pressure, and lipid panels. These are clinically meaningful outcomes, and the trials delivered on them with consistency.

What the trials did not systematically prioritize as a primary endpoint was body composition—specifically, the ratio of fat mass lost to lean mass lost during the weight-reduction period.

This is a significant omission.

A body composition substudy of the STEP 1 trial — conducted in 140 participants using dual-energy X-ray absorptiometry — found that while total fat mass decreased by 19.3% with semaglutide, total lean body mass also decreased by 9.7%. In the context of a medication that produces weight loss primarily through appetite suppression and reduced caloric intake — without a structured protocol for protein adequacy or resistance stimulus — this disproportionate loss of lean tissue alongside fat is not surprising. It is, however, alarming from a longevity and metabolic health perspective.

Wilding JPH, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study. Journal of the Endocrine Society 2021;5(Supplement_1):A16–A17. DOI: 10.1210/jendso/bvab048.030

Skeletal muscle is not simply a tissue of physical performance. It is the primary site of glucose disposal in the body — responsible for approximately 75–80% of insulin-stimulated glucose uptake under euglycemic conditions. It is a metabolically active endocrine organ that produces myokines with anti-inflammatory and neuroprotective properties. It is the single most important determinant of metabolic rate, insulin sensitivity, and functional longevity across the lifespan.

DeFronzo RA, Tripathy D. Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes. Diabetes Care 2009;32(Suppl 2):S157–S163. DOI: 10.2337/dc09-S302

When skeletal muscle is lost — as it is disproportionately lost in the context of GLP-1 induced caloric restriction without adequate nutritional support — the metabolic foundation that determines long-term weight maintenance, insulin sensitivity, and biological age is compromised. The number on the scale moves downward. The metabolic architecture beneath it becomes more fragile.

The rebound data.

Perhaps the most sobering finding in the GLP-1 literature is what happens when the medication is discontinued.

The STEP 1 extension trial followed participants for 1 year after discontinuation of semaglutide. Within that period, participants regained approximately two-thirds of their prior weight loss, and the cardiometabolic improvements largely reversed alongside it.

Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022. DOI: 10.1111/dom.14725

This finding has been interpreted by some as evidence that GLP-1 medications must be continued indefinitely to maintain their effects — a conclusion that has significant implications for cost, access, and long-term safety monitoring.

An alternative interpretation — one that the literature supports but that receives less attention in prescribing conversations — is that the weight regain reflects the absence of metabolic re-education during the medication period. The underlying signal environment that drove the original dysfunction — the hormonal dysregulation, the disrupted circadian biology, the inflammatory load, the cortisol patterns that maintain insulin resistance at the cellular level — was never addressed. The medication suppressed appetite and produced a caloric deficit. It did not change the metabolic conditions that necessitated the deficit.

When the medication was removed, the body returned to the environment it had never left.

The nutritional guidance gap.

GLP-1 medications are now prescribed across a broad range of clinical settings — primary care, endocrinology, cardiology, nephrology — each operating under significant structural constraints. Visit times averaging 15 to 18 minutes, patient panels that have grown beyond sustainable capacity, and a reimbursement model that does not adequately support extended metabolic education — these are the realities clinicians across specialties navigate every day. The absence of formal nutritional counseling alongside GLP-1 prescriptions is not a failure of individual physicians. It is a structural gap in how metabolic pharmacotherapy is currently resourced and delivered, regardless of the specialty issuing the prescription.

The result is a patient population that is losing weight — and, in many cases, losing muscle, depleting micronutrient stores, disrupting gut microbiome integrity, and altering hormonal patterns — without the foundational understanding of their own metabolic biology needed to sustain or build upon those results.

The gut microbiome and endogenous GLP-1 production.

One of the most underaddressed dimensions of GLP-1 therapy is what it does not do for the gut microbiome — and what a restored gut microbiome can do that the medication cannot.

GLP-1 receptor agonists alter gastric motility and the gastrointestinal environment, thereby affecting microbial diversity and composition. A 2025 systematic review of 38 studies found that semaglutide specifically increased Akkermansia muciniphila — a metabolically favorable genus — but also decreased overall microbial diversity. Effects varied by drug type, population, and treatment duration, and were not uniformly positive across the literature.

Gofron KK, et al. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients 2025;17(8):1303. DOI: 10.3390/nu17081303. PMID: 40284168

A compromised microbiome affects short-chain fatty acid production, intestinal permeability, systemic inflammation, and — critically — endogenous GLP-1 production. The L-cells of the gut lining produce GLP-1 naturally in response to nutrient intake. When the gut microbiome is healthy, diverse, and functioning with integrity, this endogenous production is robust. When it is compromised — as it is in the vast majority of people presenting with metabolic dysfunction — endogenous GLP-1 production is diminished, which is part of why food noise increases and appetite regulation becomes dysregulated in the first place.

This is the deeper clinical reality that the pharmacological approach does not address. The medication substitutes for a function the gut was always designed to perform. Restoring the gut microbiome — through coherent nutritional signals, fiber diversity, integration of fermented foods, and removal of inflammatory inputs — allows the body to restore that function naturally. Not as a replacement for medication in every case. As the foundation that makes the medication's effects sustainable and that eventually allows the body to regulate itself without pharmacological support.

The signal environment the medication cannot reach.

Beyond the nutritional gap lies a deeper biological reality that the GLP-1 literature has not yet fully addressed — the role of the neuroendocrine environment in determining metabolic outcomes.

Chronic HPA axis dysregulation — the sustained elevation of cortisol that characterizes modern high-demand lifestyles — maintains insulin resistance at the cellular level through mechanisms that operate independently of caloric intake. Cortisol drives hepatic glucose production, promotes visceral adiposity, downregulates insulin receptor sensitivity, and sustains the inflammatory tone that the metabolic system organizes around.

StatPearls: Physiology, Cortisol. NBK538239. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of Insulin Resistance in Skeletal Muscle. BioMed Research International 2010. PMC2860140

A GLP-1 medication does not alter cortisol patterns. It does not restore circadian biology. It does not address the autonomic nervous system dysregulation that governs metabolic rate and fuel partitioning. It does not recalibrate the hormonal rhythm — leptin, ghrelin, adiponectin, thyroid — that determines how the body interprets and responds to its nutritional environment.

These are not peripheral concerns. They are central determinants of whether the metabolic improvements produced by GLP-1 therapy are sustained, deepened, or ultimately reversed when the pharmacological appetite suppression is removed.

The food environment underlying the dysfunction.

Weight dysregulation, food noise, and metabolic dysfunction are not character flaws. They are, in significant part, the logical biological outcome of a food environment the human body was never designed to navigate.

Soil nutrient depletion has reduced the micronutrient density of whole foods by measurable margins over the past several decades. A landmark study comparing USDA nutritional data between 1950 and 1999 across 43 garden crops found reliable declines in calcium, phosphorus, iron, riboflavin, and vitamin C — ranging from 6% to 38% — attributed to high-yield agricultural practices that prioritize growth rate over nutritional density.

Davis DR, Epp MD, Riordan HD. Changes in USDA Food Composition Data for 43 Garden Crops, 1950 to 1999. Journal of the American College of Nutrition 2004;23(6):669–682. DOI: 10.1080/07315724.2004.10719409

Tens of thousands of chemicals, additives, and preservatives have entered the food supply — many with insufficient study of their cumulative effect on the gut microbiome. The result is a population whose gut integrity has been systematically compromised by environmental and agricultural realities, not by personal failure. GLP-1 medications help quiet the food noise this environment creates. For many people, they are a meaningful and appropriate clinical tool. What they cannot do is rebuild the biological foundation depleted before the patient ever arrived for the prescribing visit.

What the literature is pointing toward.

The emerging consensus in metabolic medicine is that GLP-1 medications produce their best and most durable outcomes when used as one component of a comprehensive metabolic intervention — one that includes structured nutritional guidance, protein adequacy protocols, resistance stimulus to preserve lean mass, and attention to the hormonal and neuroendocrine environment that governs metabolic function.

This is not a novel clinical insight. It is what the literature has been pointing toward since the first extension trial data became available. What has lagged behind is the translation of that insight into standard prescribing practice, which is understandable given the structural realities of modern clinical practice across specialties. The gap, however, remains.

The patients navigating these medications deserve better than a prescription without a foundation. They deserve to understand the physiology of their own metabolic biology — how their hormones respond to food timing and composition, how their nervous system influences their metabolic rate, how the signal environment they live in determines whether their body burns or stores, repairs or protects.

That understanding does not come from a prescription. It comes from education.

A clinical note on the Reset.

The Aquarian Medicine Reset™ and Intuitive Aquarian Medicine (IAM) Nutrition™ were built to address this reality precisely — restoring the conditions within the body that allow it to regulate itself with its own intelligence. For those currently on GLP-1 therapy, the Reset provides the metabolic and gut foundation that transforms a pharmacological intervention into a sustainable biological shift. For those considering GLP-1 therapy, it offers an alternative path — one that works at the level of cause rather than symptom.

The body was always capable of this regulation. It needs the conditions that make it possible.

The natural next reading from here:

→ The Body Organizes Around the Problem

The Aquarian Medicine Reset™ is offered seasonally three times per year. To learn more about the current or upcoming cycle:

→ https://www.aquarianmedicine.com/aquarian-medicine-reset-overview

The Reset Summer Cycle begins May 17, 2026. Enrollment is open through May 16.

→ https://www.aquarianmedicine.com/aquarian-medicine-reset-summer